Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Neoplasms 3Ovarian Neoplasms 2Lung Neoplasms 2Wilms Tumor 1Uterine Cervical Neoplasms 1Sarcoma 1Kidney Neoplasms 1Endocrine Gland Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Temozolomide 17Bevacizumab 10Radiotherapy 9Carmustine 9Magnetic Resonance Spectroscopy 7Erlotinib Hydrochloride 7Carboplatin 7Sorafenib 6Lapatinib 6Chemotherapy, Adjuvant 62,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 6temsirolimus 5Vorinostat 5Surgical Procedures, Operative 5Sirolimus 5Radiosurgery 5Radiation 5Dexamethasone 5cediranib 4Immunoglobulin G 4Disulfides 4Cyclophosphamide 4Cilengitide 4pazopanib 3Thalidomide 3Procarbazine 3Nivolumab 3Neoadjuvant Therapy 3Irinotecan 3Iodine-125 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Brain Neoplasms × tariquidar × Clear all
NCT00011414 2019-07-16

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
29 enrolled
CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡